Moolec Science SA

Sustained commercial adoption will keep revenue growth positive because early sales already produced a materially larger revenue base and positive gross_profit. If true, rising revenue becomes the engine to absorb fixed R&D/SG&A and deliver operating leverage; if false, the company will keep burning cash and likely dilute shareholders.

Positive gross_profit in FY2024 implies the product can have viable unit economics, but that must be sustained as volumes scale and mix shifts. Sustained gross margins are the prerequisite for operating profitability; if margins revert, revenue growth alone won't protect equity value.

Moolec must materially reduce negative operating_cash_flow or secure new financing/partner funding before cash runs too low, because current burn outpaces cash on hand. Failure to secure non-dilutive funding or to reach positive operating cash flow will force dilutive equity issuance or distress.

The large rise in liabilities indicates recent financing or obligations that could dilute equity or impose fixed costs, so the balance-sheet structure is a material risk to shareholder value if revenue growth disappoints. If liabilities are debt-like or convertible, they create leverage or dilution; if they are deferred revenue or grants, the risk is lower — the type matters more than the size.

Operating losses will only shrink if revenue scales faster than operating expenses; the current increase in operating_income losses despite revenue growth shows operating leverage is not yet realized. Operating leverage is needed to move from gross-profit to operating-profit; absent it, the company will remain chronically unprofitable despite revenue growth.